Deep Vein Thrombosis
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders.
|
31064749 |
2019 |
Deep Vein Thrombosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
We investigated SERPINC1 defects in Japanese patients with congenital AT deficiency who developed venous thromboembolism or had a family history of deep vein thrombosis.
|
31030036 |
2019 |
Deep Vein Thrombosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A novel variation of SERPINC1 caused deep venous thrombosis in a Chinese family: A case report.
|
30608445 |
2019 |
Deep Vein Thrombosis
|
0.500 |
GeneticVariation
|
disease |
CLINVAR |
Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders.
|
31064749 |
2019 |
Deep Vein Thrombosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We have identified 2 novel polymorphisms, g.25G>A and g.-1A>T, and 2 known g.67G>A and rs3138521 5' UTR polymorphisms in SERPINC1 regulatory region in Indian patients with DVT for the first time.
|
27279637 |
2017 |
Deep Vein Thrombosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Rare mutations in PROC, PROS1 or SERPINC1 as well as common variants in F5, F2, F11 and SERPINC1 have been identified as risk factors for deep vein thrombosis (DVT).
|
26982741 |
2016 |
Deep Vein Thrombosis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We screened 1950 deep vein thrombosis (DVT) patients for AT activity and antigen levels.
|
25811371 |
2015 |
Deep Vein Thrombosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We report here the first heterozygous deletion of SERPINC1 exon 1 identified in a 44-year-old man with type I deficiency who developed deep vein thrombosis of the left leg complicated by pulmonary embolism.
|
25083771 |
2015 |
Deep Vein Thrombosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Deep vein thrombosis (DVT) has a strong inherited predisposition that is partly explained by the strong genetic risk factors such as mutations in factor V, prothrombin, antithrombin III, protein C and S genes.
|
25091233 |
2014 |
Deep Vein Thrombosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Comparison of activated partial thromboplastin time, antithrombin III, D-dimer, lupus anticoagulant, free S protein (PS), C protein, and antiphospholipid and PS antibodies was performed on children with acute VZV and DVT (group I), acute uncomplicated VZV (group II), and 30 healthy controls of both sexes (15 boys and 15 girls, mean age 7.5 ± 2.6 years, group III).
|
23321260 |
2013 |
Deep Vein Thrombosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Patients identified preoperatively as having a personal or familial history of DVT and/or PE were referred for hemostatic serum and genetic tests, including % antithrombin III activity (ATIII), protein C and protein S activities, APC resistance, Factor V gene (Leiden) mutations, prothrombin gene mutations, lupus anticoagulant antibody presence, cardiolipin antibody presence, phosphatidyl antibody presence, β2-glycoprotein antibody presence, and serum homocysteine and lipoprotein(a) levels The frequencies of varying abnormalities were identified and compared to the prevalence reported in the literature.
|
20824408 |
2011 |
Deep Vein Thrombosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Genetic deficiencies of PROS1, PROC, and SERPINC1 (antithrombin) are risk factors for deep vein thrombosis (DVT).
|
18954896 |
2009 |
Deep Vein Thrombosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Of 9 SNPs genotyped in MEGA-2, 3 were strongly associated with DVT (P < .05; false discovery rate < or =.10): rs13146272 in CYP4V2 (risk allele frequency, 0.64), rs2227589 in SERPINC1 (risk allele frequency, 0.10), and rs1613662 in GP6 (risk allele frequency, 0.84).
|
18349091 |
2008 |
Deep Vein Thrombosis
|
0.500 |
Biomarker
|
disease |
CTD_human |
Effect of critical injury on plasma antithrombin activity: low antithrombin levels are associated with thromboembolic complications.
|
8810955 |
1996 |
Deep Vein Thrombosis
|
0.500 |
Biomarker
|
disease |
CTD_human |
[Treatment of deep venous thrombosis in the presence of a congenital antithrombin III deficiency. Apropos of the use of purified concentrates].
|
6435583 |
1984 |
Deep Vein Thrombosis
|
0.500 |
Biomarker
|
disease |
CTD_human |
Oral contraceptives, antithrombin- III activity, and postoperative deep-vein thrombosis.
|
55783 |
1976 |
Deep Vein Thrombosis
|
0.500 |
Biomarker
|
disease |
HPO |
|
|
|